Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis
EndocrinologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- The Journal of clinical endocrinology and metabolism
- Publicado em
- 16 set 2024
- Citações
- 9
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis
Ren Jing, Nan Wu, Yang Wu, Qian Zhang, Qiankun Liang, Peng Huang, Shijian Yi
Descritores MeSH
- Thyroid Neoplasms
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Humans
- Indoles
- Phenylurea Compounds
- Sorafenib
- Quinolines
- Treatment Outcome
- Carcinoma, Medullary
Veja também
Estudos relacionados
- Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study
- Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials
- Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis
- Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis